Belcastro S, De Blasi A, Berti Donini G, Pavanelli L, Buccoliero C
Minerva Med. 1985 Nov 17;76(44):2131-4.
A 40 year old woman who took a daily dose of 2-4 mg of Ergotamine Tartrate (Cafergot) regularly for 6 years to combat persistent migraine, was treated for a non-atherosclerotic arterial disease, severe arteriospasm of the great limb arteries, hyperplasia of the intima and segmental thrombosis. Binding of adrenergic alpha and beta receptors was investigated. Surprisingly it was found that the number of adrenergic beta receptors was significantly lower thant that of a healthy woman of the same age used as a control while the number of alpha receptors was not significantly different. This action of ergotamine on beta receptors could be explained by a dopamine-mimetic stimulation, due to the central nervous system, that could lead to the preferential regulation of beta receptors rather than alpha receptors, almost as a protective mechanism of alpha receptors.
一名40岁女性,为对抗持续性偏头痛,连续6年每日规律服用2 - 4毫克酒石酸麦角胺(卡非吉),现因非动脉粥样硬化性动脉疾病、下肢大动脉严重动脉痉挛、内膜增生和节段性血栓形成接受治疗。对肾上腺素能α和β受体的结合情况进行了研究。令人惊讶的是,发现与作为对照的同年龄健康女性相比,肾上腺素能β受体数量显著降低,而α受体数量无显著差异。麦角胺对β受体的这种作用可以用中枢神经系统产生的多巴胺模拟刺激来解释,这种刺激可能导致β受体而非α受体的优先调节,几乎像是α受体的一种保护机制。